Q-omics provides the consensus-scored LINC00266-1 profile across patient tissues and cancer cell-line models. LINC00266-1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC00266-1 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, LINC00266-1 RNA expression shows 12,219 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, PAAD, and UVM as cancer lineages where LINC00266-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00266-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00266-1 survival associations across molecular data types. LINC00266-1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00266-1 RNA expression–survival associations across cancer types. High LINC00266-1 expression shows unfavorable associations in MESO, THCA, KIRP, KICH and CESC, but favorable associations in ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for LINC00266-1 RNA expression.
This table summarizes LINC00266-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00266-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00266-1 shows lower tumor expression in PAAD, UCEC, KIRP and KIRC. The PAAD box plot shows higher LINC00266-1 RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p = .005).
This table shows molecular features associated with LINC00266-1 in patient tissues and cancer cell lines. In patient samples, LINC00266-1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
